L’Oréal is raising its stake in Galderma from 10% to 20%, strengthening its position in the fast-growing medical aesthetics market. The increased investment follows Galderma’s strong performance and rising demand for injectable treatments.

The beauty group first acquired a minority stake in 2023, shortly after forming a long-term partnership focused on dermatology and aesthetic innovations. With this latest move, L’Oréal aims to deepen its collaboration with Galderma on science-based skincare and expand its reach in the professional aesthetics segment.

Galderma, known for brands such as Restylane, Cetaphil, and Sculptra, has continued to grow globally as consumers seek more personalized skin treatments. The company said the expanded partnership will support research, product development, and future growth initiatives.

The transaction is expected to be completed in early 2025, subject to regulatory approval.